Cargando…

1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections

BACKGROUND: Limited data exist to evaluate safety-related outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) patients treated with antimicrobial agents for Gram-positive infections. METHODS: This retrospective, single-center study enrolled Mayo Clinic OPAT patients between 2013 and 2017....

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Bradley, Rivera, Christina, Dierkhising, Ross, Estes, Lynn, O’Horo, John, Tande, Aaron, Zeuli, John, Virk, Abinash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253541/
http://dx.doi.org/10.1093/ofid/ofy210.1076
_version_ 1783373519214608384
author Smith, Bradley
Rivera, Christina
Dierkhising, Ross
Estes, Lynn
O’Horo, John
Tande, Aaron
Zeuli, John
Virk, Abinash
author_facet Smith, Bradley
Rivera, Christina
Dierkhising, Ross
Estes, Lynn
O’Horo, John
Tande, Aaron
Zeuli, John
Virk, Abinash
author_sort Smith, Bradley
collection PubMed
description BACKGROUND: Limited data exist to evaluate safety-related outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) patients treated with antimicrobial agents for Gram-positive infections. METHODS: This retrospective, single-center study enrolled Mayo Clinic OPAT patients between 2013 and 2017. The primary objective of the study compared rates of therapy modification due to drug-related toxicity for staphylococcal infections treated with ceftriaxone, cefazolin, nafcillin, oxacillin, vancomycin, daptomycin, ceftaroline, linezolid, or ertapenem. Secondary objectives included determination of the frequency and type of adverse drug events (ADEs) attributed to OPAT and rate of readmission due to ADEs attributed to OPAT. RESULTS: One hundred seventy-two patients were identified (cefazolin n = 54, ceftriaxone n = 49, vancomycin n = 30, daptomycin n = 16, nafcillin n = 9, ertapenem n = 6, ceftaroline n = 4, oxacillin n = 3, linezolid n = 1). The overall treatment completion rates were high (153/172, 89.0%). Patients completed an average of 35.3 days (7 to 95) of therapy with their original antibiotic. Fourteen patients required change to a different antibiotic due to antimicrobial toxicity (ceftriaxone=5; vancomycin=2; cefazolin = 2; daptomycin = 2; ceftaroline = 1; nafcillin = 1; oxacillin = 1) and five patients experienced treatment failure required an additional agent (ceftriaxone = 2; nafcillin = 2; linezolid = 1). Adverse drug events (ADEs) were the most common reason for antimicrobial adjustment (14/19, 73.7%). The most common ADEs were hypokalemia (28/172, 16.3%) and diarrhea (25/172, 14.5%). There were only two cases of Clostridium difficile. Thirty-day readmissions due to antimicrobial therapy were low with 11 patients. CONCLUSION: OPAT with Gram-positive agents used for staphylococcal infections is effective, but antimicrobial modifications still occur. Clinicians should be aware of the risk of ADEs and readmissions in OPAT patients. A multidisciplinary approach may enhance management of ADEs and possibly preventing readmissions DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253541
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62535412018-11-28 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections Smith, Bradley Rivera, Christina Dierkhising, Ross Estes, Lynn O’Horo, John Tande, Aaron Zeuli, John Virk, Abinash Open Forum Infect Dis Abstracts BACKGROUND: Limited data exist to evaluate safety-related outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) patients treated with antimicrobial agents for Gram-positive infections. METHODS: This retrospective, single-center study enrolled Mayo Clinic OPAT patients between 2013 and 2017. The primary objective of the study compared rates of therapy modification due to drug-related toxicity for staphylococcal infections treated with ceftriaxone, cefazolin, nafcillin, oxacillin, vancomycin, daptomycin, ceftaroline, linezolid, or ertapenem. Secondary objectives included determination of the frequency and type of adverse drug events (ADEs) attributed to OPAT and rate of readmission due to ADEs attributed to OPAT. RESULTS: One hundred seventy-two patients were identified (cefazolin n = 54, ceftriaxone n = 49, vancomycin n = 30, daptomycin n = 16, nafcillin n = 9, ertapenem n = 6, ceftaroline n = 4, oxacillin n = 3, linezolid n = 1). The overall treatment completion rates were high (153/172, 89.0%). Patients completed an average of 35.3 days (7 to 95) of therapy with their original antibiotic. Fourteen patients required change to a different antibiotic due to antimicrobial toxicity (ceftriaxone=5; vancomycin=2; cefazolin = 2; daptomycin = 2; ceftaroline = 1; nafcillin = 1; oxacillin = 1) and five patients experienced treatment failure required an additional agent (ceftriaxone = 2; nafcillin = 2; linezolid = 1). Adverse drug events (ADEs) were the most common reason for antimicrobial adjustment (14/19, 73.7%). The most common ADEs were hypokalemia (28/172, 16.3%) and diarrhea (25/172, 14.5%). There were only two cases of Clostridium difficile. Thirty-day readmissions due to antimicrobial therapy were low with 11 patients. CONCLUSION: OPAT with Gram-positive agents used for staphylococcal infections is effective, but antimicrobial modifications still occur. Clinicians should be aware of the risk of ADEs and readmissions in OPAT patients. A multidisciplinary approach may enhance management of ADEs and possibly preventing readmissions DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253541/ http://dx.doi.org/10.1093/ofid/ofy210.1076 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Smith, Bradley
Rivera, Christina
Dierkhising, Ross
Estes, Lynn
O’Horo, John
Tande, Aaron
Zeuli, John
Virk, Abinash
1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
title 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
title_full 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
title_fullStr 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
title_full_unstemmed 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
title_short 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
title_sort 1243. comparative analysis of antimicrobial-related adverse events in the outpatient treatment of staphylococcal infections
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253541/
http://dx.doi.org/10.1093/ofid/ofy210.1076
work_keys_str_mv AT smithbradley 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT riverachristina 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT dierkhisingross 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT esteslynn 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT ohorojohn 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT tandeaaron 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT zeulijohn 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections
AT virkabinash 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections